Recently, emerging evidence has demonstrated the differential expression of REG3A in patients with diabetes, inflammatory bowel disease (IBD), and cancers, which may suggest an important physiological function of REG3A [23–25]. This evidence concerns the gene REG3A and diabetes mellitus.